In 2012, Agios Pharmaceuticals identified the first small molecule selective inhibitor of mutated IDH (in this case specific to the R132H IDH1 mutation) via high throughput screening, with subsequent demonstrations of delayed growth and increased differentiation of stem-like tumor IDH-mutant glioma cells [18,19]. Here, IDH2 is linked to central nervous system cancer.